Table 2.
Selected clinical and laboratory variables of subgroup of cats with GFR performed (n = 10) before (T0) and 1 month after (T1) radioiodine treatment provided as median (range)
| Variables (RI + units) | T0 | T1 | Median of difference between T1 and T0 | P |
|---|---|---|---|---|
| Age (years) | 12.5 (8‐15) | |||
| BW (kg) | 4.0 (2.6‐5.1) | 4.2 (2.9‐5.1) | 0.3 (0‐0.6) | <.001 |
| MCS | Normal; n = 2 (20%) | Normal; n = 7 (70%) | Improved | <.001 |
| Mild loss; n = 4 (40%) | Mild loss; n = 3 (30%) | |||
| Moderate loss; n = 3 (30%) | ||||
| Severe loss; n = 1 (10%) | ||||
| BP (mm Hg) | 163 (140‐225) | 170 (125‐200) | 5 (−10 to 50) | .67 |
| Serum TT4 (0.8‐4.7 μg/dL) | 10 (4.8‐>13) | 0.8 (<0.7‐1.3) | −8.9 (<−12.2 to −3.5) | <.001 |
| Serum creatinine (0.9‐2.3 mg/dL) | 0.66 (0.39‐1) | 1.21 (0.97‐1.5) | 0.54 (0.27 to 0.85) | <.001 |
| Serum SDMA (0–14 μg/dL) | 9.5 (4‐15) | 11 (7‐17) | 2.5 (−5 to 8) | .2 |
| USG | >1.050 (1.040‐>1.050) | >1.050 (1.032‐>1.050) | 0 (−0.008 to 0.010) | .42 |
| GFR (≥1.9 mL/min/kg) | 3.65 (2.1‐5) | 2.15 (0.9‐3.4) | −1.7 (−2.2 to −0.1) | .002 |
Abbreviations: BCS, body condition score; BP, blood pressure; BW, body weight; MCS, muscle condition score; RI, reference interval; SDMA, symmetric dimethylarginine; TSH, serum thyroid‐stimulating hormone; TT4, serum total thyroxine; UPC, urinary protein : creatinine ratio; USG, urine specific gravity.